First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI

Giuseppe Saglio, Elias Jabbour

Research output: Contribution to journalReview articlepeer-review

24 Scopus citations

Abstract

Patients diagnosed with chronic myeloid leukemia (CML) and treated with BCR-ABL1 tyrosine kinase inhibitors (TKIs) have long life spans. Selection of an appropriate first-line therapy can be difficult as both the unique characteristics of each TKI and patient need to be taken into account to find the optimal match. Patient characteristics include comorbidities, concomitant medications, lifestyle, risk factors, BCR-ABL1 transcript type (e.g. b2a2 or b3a2) and additional chromosomal abnormalities. Just as patients differ, side effects, drug-drug interactions, administration plans, dosing schedules and treatment-related expenses across TKIs also vary. Alignment of these characteristics with the appropriate TKI is key to successfully initiating CML treatment. Continued success relies on communication between the patient and the healthcare team, adherence and optimization of therapy once it is initiated. In this review, we discuss these factors, in addition to TKI efficacy and safety, the cost of therapy, the future of treating CML and treatment-free remission.

Original languageEnglish (US)
Pages (from-to)1523-1538
Number of pages16
JournalLeukemia and Lymphoma
Volume59
Issue number7
DOIs
StatePublished - Jul 3 2018

Keywords

  • Myeloid leukemias and dysplasias
  • myeloproliferative disorders
  • signaling therapies

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI'. Together they form a unique fingerprint.

Cite this